Hydroxyurea therapy for sickle cell anemia.

  title={Hydroxyurea therapy for sickle cell anemia.},
  author={Patrick T McGann and Russell E Ware},
  journal={Expert opinion on drug safety},
  volume={14 11},
INTRODUCTION Sickle cell anemia (SCA) is a severe, inherited hemoglobin disorder affecting 100,000 persons in the US and millions worldwide. Hydroxyurea, a once daily oral medication, has emerged as the primary disease-modifying therapy for SCA. The accumulated body of evidence over 30 years demonstrates that hydroxyurea is a safe and effective therapy for SCA, but hydroxyurea remains underutilized for a variety of reasons. AREAS COVERED In this review, we summarize the available evidence… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS